ReviewFrontiers in oncology2024
Potential role of the Eph/ephrin system in colorectal cancer: emerging druggable molecular targets.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- CLK3 regulates tumor angiogenesis by modulating HIF1α ubiquitination.Cancer gene therapy · 2026Article
- Decoding the Apical-Basal Surfaceome of Colon Epithelial Cells via Side-Selective Biotinylation.Biomolecules · 2026Article
- Epigenome-wide association study of blood proteome in the Atherosclerosis Risk in Communities study.HGG advances · 2026Article
- Mechanistic study of deoxycholic acid in colorectal cancer based on network toxicology and machine learning approaches.BMC pharmacology & toxicology · 2026Article
- Ephrin B3 drives tumorigenesis and inflammation in cutaneous squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2025Article
- ABCE1 facilitates tumour progression via aerobic glycolysis and inhibits cell death in human colorectal cancer cells through the p53 signalling pathway.Scientific reports · 2025Article
- Tissue microarray and liquid biopsy approaches identify EphB3, cMet, and miR-3168 as biomarkers of colorectal cancer.Cell cycle (Georgetown, Tex.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
The Eph/ephrin system regulates many developmental processes and adult tissue homeostasis. In colorectal cancer (CRC), it is involved in different processes including tumorigenesis, tumor angiogenesis, metastasis development, and cancer stem cell regeneration. However, conflicting data regarding Eph receptors in CRC, especially in its putative role as an oncogene or a suppressor gene, make the precise role of Eph-ephrin interaction confusing in CRC development. In this review, we provide an overview of the literature and highlight evidence that collaborates with these ambiguous roles of the Eph/ephrin system in CRC, as well as the molecular findings that represent promising therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.